DataMeds AI Licenses GLP-1 AI Platform, Pays in Stock, Says It Regained Nasdaq Equity Compliance

What happened

DataMeds AI, Inc. (Nasdaq: MEDS), a Tampa-based company in the wholesale-drugs and druggists' sundries business, disclosed in a Form 8-K filed October 16, 2026 that on October 13 it entered an Intellectual Property License and Product and Services Agreement with REBOOT Health AI, Inc., a Delaware corporation.

Under the agreement, REBOOT granted DataMeds an exclusive license in the United States to REBOOT's licensed patents and to use the REBOOT Health AI Platform. The exclusivity is limited to the "Field of Use," defined in the filing as use of the REBOOT AI platform for managing GLP-1 users in connection with DataMeds' GLP-1 weight-management business, and limited to DataMeds' direct-to-consumer business model. DataMeds is not licensed to sell services using the REBOOT technology directly to healthcare providers for healthcare business use, subject to limited listed exceptions.

DataMeds will pay for the license with 666,667 shares of its common stock. If, 180 days after the effective date, those shares are worth less than $2,000,000, the company must issue additional shares to cover the shortfall, based on the 10-day volume-weighted average price of its stock at that time.

The filing also states that REBOOT will provide products and services to DataMeds under a related Product and Services Agreement, and will receive a share of DataMeds' Adjusted Gross Revenue, as defined in the license, generated from use of the REBOOT technology after certain costs are deducted. DataMeds agreed to pay REBOOT $50,000 within two business days toward reconfiguring the REBOOT platform into the "DataMeds Platform," a scope of work the parties estimate will cost at least $100,000 in total.

The license continues until the last of the licensed patents expires or is invalidated, subject to earlier termination for an uncured material breach after 30 days' written notice and to minimum revenue thresholds. DataMeds said it will file the full agreement as an exhibit to its Form 10-Q for the quarter ended September 30, 2026.

The Nasdaq equity deficiency

The same filing addresses a separate matter: a deficiency letter DataMeds received from Nasdaq's Listing Qualifications Department on April 13, 2026, previously disclosed in an April 21, 2026 filing. Nasdaq told the company that, based on stockholders' equity of negative $12,447,801 reported for the fiscal year ended December 31, 2025, it no longer met the $2,500,000 minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1), and that it also did not meet the rule's alternative standards based on market value of listed securities or net income from continuing operations.

The company said several transactions since then increased its stockholders' equity: converting about $1.5 million of vendor payables into common stock between July and October 2026; issuing 636,328 shares to Axe Computer, Inc. to acquire Helomics Corporation, disclosed in a September 16, 2026 filing; a settlement agreement disclosed September 17, 2026 that extinguished about $18.7 million of debt; and the 666,667 shares issued to REBOOT, valued at $2,000,000.

DataMeds said it believes it now has in excess of $2,500,000 in stockholders' equity and is awaiting Nasdaq's formal confirmation that it has demonstrated compliance. Nasdaq will continue to monitor the requirement, and the company said it could face delisting proceedings if it does not evidence compliance at its next periodic report.

What this means

An 8-K is the form a US public company files with the SEC to disclose material events between its regular quarterly and annual reports. The item numbers in the filing point to the specific disclosure obligations: Item 1.01 for a material definitive agreement, Item 3.01 for a notice of failure to satisfy a continued listing rule, and Item 3.02 for unregistered sales of equity securities.

GLP-1 drugs are a class of medicines, including semaglutide and tirzepatide, used for diabetes and weight loss. DataMeds' license covers software for managing patients or customers using those drugs, and only in its direct-to-consumer business — not for sale to doctors or clinics. REBOOT keeps ownership of the platform and its code; DataMeds may not modify or reverse engineer it, so the license grants use, not control, of the technology.

Paying for the license in stock rather than cash is why the company also filed under Item 3.02. The shares were issued under an exemption from SEC registration — Section 4(a)(2) of the Securities Act and/or Regulation D — for transactions not involving a public offering. The shares are "restricted securities" under Rule 144, meaning they carry holding-period limits before they can be resold, and the company granted REBOOT piggy-back registration rights in connection with any underwritten public offering that permits secondary shares. The shortfall clause means the effective price to REBOOT is not fixed: if the stock is worth less than $2 million in 180 days, DataMeds issues more shares, diluting existing holders.

Nasdaq's $2.5 million stockholders' equity rule is one of several tests a company can use to stay listed. Stockholders' equity is a company's assets minus its liabilities — book value, not market value — and a deficit means liabilities exceed assets. Converting payables and debt into stock removes liabilities and increases equity on the balance sheet, which is how these transactions address a deficiency even without any cash coming in. The filing does not say why the company's equity was negative in the 2025 fiscal year.

Based on the filing, the next step is Nasdaq's written confirmation, which the company says it is awaiting. The filing also notes that if DataMeds does not show compliance at its next periodic report, it could face delisting proceedings.

Market reaction

DataMeds shares closed at $2.63 on the event date, down 7.72% from the previous close of $2.85, according to the price data. The filing does not attribute the move to any specific cause.